Real-world Effectiveness of Sarilumab in RA: Results from the Open-label, Prospective, Single-arm Observational PROFILE Study
In this 1-year, observational real-world study, sarilumab therapy resulted in improved clinical outcomes. The safety profile was consistent with that observed in sarilumab randomized clinical trials. This study was entered on the German website (Paul Ehrlich Institute) on January 11, 2018, with NIS No.: 423.
Authors
- Hubert van Hoogstraten
- Martin Bergman (ORCID: https://orcid.org/0000-0002-8948-5264)
- Louis Bessette (ORCID: https://orcid.org/0000-0002-6834-2731)
- Alan Kivitz (ORCID: https://orcid.org/0000-0002-1045-1310)
- Ron de Nijs
- Jacques Éric Gottenberg
- Chunfu Qiu
Institutions
- Sanofi (United States) (US)
- Altoona Center for Clinical Research (US)
- Elkerliek Ziekenhuis (NL)
- Hôpitaux Universitaires de Strasbourg (FR)
- Hôpital d'Hautepierre (FR)
- Université Laval (CA)
- Drexel University (US)
Publication Details
- Journal
- Rheumatology and Therapy
- Published
- 2024-09-16
- DOI
- https://doi.org/10.1007/s40744-024-00715-9
- Citations
- 1
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- Sanofi
- Regeneron Pharmaceuticals